VivoSim Labs, INC. (VIVS)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.17
- As of
Kresmion compiles this page from VIVS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
VivoSim Labs, INC. (VIVS): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-06.
See the full VIVS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for VIVS on one page. Preview it with sample data, then open it live with a free account.
Preview the VIVS dossierActive signals for VIVS
- mediumNEW_POSITION
RENAISSANCE TECHNOLOGIES LLC new position in VIVS
- mediumEARNINGS_MISS
Q4-2025: Missed consensus by 1040.4% - EPS $-2.21 vs $-0.1938 estimate
- mediumEARNINGS_BEAT
Q4-2024: Beat consensus by 32.3% - EPS $-3.48 vs $-5.1408 estimate
- mediumEARNINGS_BEAT
Q1-2025: Beat consensus by 31.7% - EPS $-2.76 vs $-4.0392 estimate
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 47.2% - EPS $-1.68 vs $-3.1824 estimate
FREE, NO ACCOUNT
Every signal on VIVS, as it fires
You are seeing 5 of 6 signals recorded on VIVS since 2026-05-24.
The five above landed across 3 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in VIVS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 68620A302 · 2026Q2 | $20K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, VIVS
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
VIVS against its peers
VIVS's operating margin of -8768.7% ranks in the 39th percentile of 8 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | VIVS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 131000 USD | 215901 USD | 50 | 8 |
| Revenue YoY | -9.0% | n/a | n/a | 0 |
| Gross margin | n/a | 38.6% | n/a | 7 |
| Operating margin | -8768.7% | -5143.5% | 39 | 8 |
| Net margin | -10567.2% | -4911.4% | 39 | 8 |
| Return on equity | n/a | -213.4% | n/a | 14 |
| 1 year | -94.3% | -92.9% | 45 | 9 |
Peers (16): SILO, MTNB, GOVX, ADTX, PPCB, BRTX, JUNS, REVB, APVO, SXTP, ACUT, CVKD, ONCO, MBIO, HCWB, PPBT. Left out: NYMXF (period gap), VCNX (period gap), LSBCF (period gap), XRTX (no annual filing), VRAX (period gap), BIXT (no annual filing), ELAB (no annual filing), GPLL (period gap), MLEC (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (VIVS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow VIVS on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to VIVS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.